Doctor taking notes

Resources

Publications

Aug 2020
Pharmacokinetics of DUR-928 in Alcoholic Hepatitis Patients – A Phase 2a Study
Jaymin Shah, Christina Blevins, Deborah Scott, Andy Miksztal, and WeiQi Lin | The European Association for the Study of the Liver (EASL)
Nov 2019
Safety and Efficacy of DUR-928: A Potential New Therapy for Acute Alcoholic Hepatitis 
Tarek Hassanein, Lance L Stein, Steven L Flamm, Paul Martin, Matthew C. Cave, Christina Blevins, Deborah Scott, William Krebs, and WeiQi Lin | American Association for the Study of Liver Diseases (AASLD) The Liver Meeting
Nov 2019
Safety and Efficacy of DUR-928: A Potential New Therapy for Acute Alcoholic Hepatitis
Tarek Hassanein, Lance L Stein, Steven L Flamm, Paul Martin, Matthew C. Cave, Christina Blevins, Deborah Scott, William Krebs, and WeiQi Lin | American Association for the Study of Liver Diseases (AASLD) The Liver Meeting
Nov 2019
DUR-928 THERAPY FOR ACUTE ALCOHOLIC HEPATITIS: A PILOT STUDY 
Craig McClain, Vatsalya, Tarek I. Hassanein, Lance L Stein, Steven L Flamm, Paul Martin, Matthew Cave, and WeiQi Lin | American Association for the Study of Liver Diseases (AASLD) The Liver Meeting
Apr 2019
Pharmacokinetic and Pharmacodynamic Response in Individual NASH Patients Receiving Two Dose Levels of DUR-928 
Jaymin Shah, Dave Ellis, William Kemp, Jim Brown, and WeiQi Lin | NASH Summit

Factsheets

See the resources included here for more information and resources from DURECT.

Scroll to Top